New look at Lutetium-177 for tough prostate cancers

NCT ID NCT07477756

Completed Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at over 1,200 men with advanced prostate cancer who received a radioactive drug called Lutetium-177 vipivotide tetraxetan in real-world clinics. Researchers tracked patient characteristics, treatment patterns, and PSA level reductions. The goal was to see how the drug performs outside of clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lutetium-177 vipivotide tetraxetan (a radioactive drug that targets prostate cancer cells)
What this could lead to: If successful, this could help doctors understand how well this treatment works in everyday practice, not just in controlled trials.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient selection and other factors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Novartis

East Hanover, New Jersey, 07936, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.